Erlenpine Generic Name Irbesartan Hydrochlorothiazide Tablets and Ambevi Generic Name Irbesartan Tablets, the former is generally more effective in lowering blood pressure than the latter, and efficacy varies from person to person. Irbesartan Hydrochlorothiazide Tablets are indicated in patient populations that are eligible for Irbesartan or Hydrochlorothiazide alone, neither of which is effective in controlling blood pressure. Contraindications include women who have been pregnant for 4 to 9 months and breastfeeding women, those with severe hepatic or renal impairment, intractable hypercalcemia or hypokalemia, biliary cirrhosis, cholestasis, and those who are allergic to the product. Irbesartan tablets are suitable for the treatment of primary hypertension and type 2 diabetic nephropathy combined with hypertension groups. It should be contraindicated in people who are allergic to the product, women who have been pregnant for 4 to 9 months and breastfeeding women, avoiding the combination of aliskiren during the use of the product in people with diabetes mellitus or moderately severe renal impairment, and in people with diabetic nephropathy, also avoiding the combination of angiotensin-converting enzyme inhibitors during this period. Theoretically, Irbesartan Hydrochlorothiazide Tablets can treat patients who cannot effectively lower their blood pressure after using Irbesartan Tablets alone, so the former’s antihypertensive effect is generally better, and the use of specific medications should be guided by a specialist physician to pay attention to the two medications can occur during the treatment of dizziness, fatigue, nausea, vomiting and other adverse reactions.